New drug cocktail aims to shrink Hard-to-Treat esophageal tumors
NCT ID NCT07700667
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This phase II trial tests a new drug called SKB500 in combination with standard chemotherapy and immunotherapy for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The study will evaluate how well the combination shrinks tumors and how safe it is. Participants receive the drugs by infusion every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of SKB500, tislelizumab, cisplatin, and 5-FU
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced esophageal cancer that is hard to treat.
- What could go wrong
- This is an early phase II trial with a moderate number of participants, so results may not confirm effectiveness. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Dalian University of Technology
Shenyang, China
-
Cancer Hospital of Shandong First Medical University
Jinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chengdu Fifth People's Hospital
Chengdu, China
-
Chongqing University Three Gorges Hospital
Chongqing, China
-
Fujian Cancer Hospital
Fuzhou, China
-
Guangxi Medical University Cancer Hospital
Nanning, China
-
Harbin Medical University Cancer Hospital
Ha’erbin, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Jiangsu Cancer Hospital
Nanjing, China
-
Jiangsu Province Hospital
Nanjing, China
-
Jilin Cancer Hospital
Changchun, China
-
Shanxi Cancer Hospital
Taiyuan, China
-
Shiyan Renmin Hospital
Shiyan, China
-
Sichuan Cancer Hospital & Institute
Chengdu, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
-
West China Hospital, Sichuan University
Chengdu, China
-
Yichang Central People's Hospital
Yichang, China
-
Yunnan Cancer Hospital
Kunming, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads
- Could a genetic marker guide future cancer therapies in taiwan?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Smart T-Cell engager aims to outsmart tumors in first human test
- DNA clues may reveal which esophageal cancers will return soon after surgery